Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women
- 1 September 1997
- Vol. 28 (1) , 75-81
- https://doi.org/10.1016/s0378-5122(97)00059-5
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Estrogenic soybean isoflavones and chronic diseaseTrends in Endocrinology & Metabolism, 1995
- Postmenopausal Bone Loss of the Proximal FemurMenopause, 1995
- Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonistsBone and Mineral, 1994
- Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosisBone and Mineral, 1993
- Effects of ipriflavone administration on bone mass and metabolism in ovariectomized womenJournal of Endocrinological Investigation, 1993
- Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of ratsCalcified Tissue International, 1992
- Effects of ipriflavone and its metabolites on a clonal osteoblastic cell lineJournal of Bone and Mineral Research, 1991
- Western diet and Western diseases: Some hormonal and biochemical mechanisms and associationsScandinavian Journal of Clinical and Laboratory Investigation, 1990
- Effect of ipriflavone on glucocorticoid-induced osteoporosis in ratsLife Sciences, 1986
- Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis.Journal of Clinical Investigation, 1981